<p>波士顿，2026 年 5 月 19 日（全球新闻通讯社）——Aura Biosciences, Inc.（纳斯达克：AURA）（“Aura” 或 “公司”）是一家临床阶段的生物技术公司，专注于开发旨在保护器官功能的实体肿瘤精准疗法。今天宣布，诱导性股权奖励（统称 “诱导奖励”）于 2026 年 5 月 19 日（“授予日期”）授予了 Aura 的新首席执行官兼总裁 Natalie Holles。诱导奖励符合 Holles 女士的聘用信中先前披露的条款，并已根据纳斯达克上市规则 5635(c)(4) 获得公司董事会的批准。</p>
<p>诱导奖励包括（i）非合格股票期权，购买公司普通股（“普通股”）共计 2,169,103 股，行使价格为每股 7.39 美元，该价格等于授予日期纳斯达克报告的普通股收盘价（“期权奖励”）；（ii）600,118 股普通股的限制性股票单位（“RSUs”）；以及（iii）553,844 股普通股的基于业绩的限制性股票单位（“PRSUs”）。期权奖励的归属如下：25% 将在 2027 年 4 月 30 日归属并可行使，之后每月归属 2.0834%，在接下来的 36 个月内归属，前提是 Holles 女士在每个归属日期继续服务。RSUs 的归属如下：25% 将在 2027 年 4 月 15 日（“首次归属日期”）归属，之后在首次归属日期的第一年、第二年和第三年周年各归属 25%，前提是 Holles 女士在每个归属日期继续服务。PRSUs 将同时受到基于时间的归属和业绩条件的限制，只有在满足这两个条件后，PRSUs 才会被视为归属。PRSUs 将在首次归属日期开始的四个基本相等的年度分期中归属，前提是 Holles 女士在每个基于时间的归属日期继续服务，并满足业绩条件。PRSUs 的到期日为（i）授予日期的第六（6）周年或（ii）Holles 女士不再与公司有服务关系的日期，以较早者为准。在该到期日之前未归属的 PRSUs 将被没收，且不予任何补偿。</p>
<p><strong>关于 Aura Biosciences</strong></p>
<p>Aura Biosciences, Inc.是一家临床阶段的生物技术公司，专注于开发旨在保护器官功能的实体肿瘤精准疗法。Aura 的主要候选药物 bel-sar（AU-011）目前正在针对早期脉络膜黑色素瘤进行后期开发，并在其他眼肿瘤适应症和膀胱癌中进行早期开发。Aura 总部位于马萨诸塞州波士顿。Aura 的使命是成长为一家创新的全球肿瘤公司，积极改变患者的生活。</p>
<p>欲了解更多信息，请访问 aurabiosciences.com。关注我们在 X 上的动态，@AuraBiosciences，并访问我们的 LinkedIn 页面。</p>
<p><strong>投资者和媒体关系联系人：</strong></p>
<p>Alex Dasalla</p>
<p>投资者关系和企业传播负责人</p>
<p>IR@aurabiosciences.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU16TTROQ00zTmpFeU1USXhJelV3TURFeU5ESTJNQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU16TTROQ00zTmpFeU1USXhJelV3TURFeU5ESTJNQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzQ5MDAxZTUtMmZjNi00OGIzLWI4OGQtN2M5N2Y3Y2FiNWViLTUwMDEyNDI2MC0yMDI2LTA1LTE5LWVu/tiny/Aura-Biosciences-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzQ5MDAxZTUtMmZjNi00OGIzLWI4OGQtN2M5N2Y3Y2FiNWViLTUwMDEyNDI2MC0yMDI2LTA1LTE5LWVu/tiny/Aura-Biosciences-Inc-.png"/></p>

AURA

<p>Aura Biosciences, Inc. 宣布根据纳斯达克上市规则 5635(c)(4) 向其新任首席执行官 Natalie Holles 授予诱导性股权奖励。该奖励包括 2,169,103 股的股票期权、600,118 股的限制性股票单位和 553,844 股的基于业绩的限制性股票单位。授予的归属时间表已列出，期权和限制性股票单位的归属取决于持续服务。Aura 专注于针对实体肿瘤的精准治疗，总部位于波士顿</p>

<p>BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles’ offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>波士顿，2026 年 5 月 19 日（全球新闻通讯社）——Aura Biosciences, Inc.（纳斯达克：AURA）（“Aura” 或 “公司”）是一家临床阶段的生物技术公司，专注于开发旨在保护器官功能的实体肿瘤精准疗法。今天宣布，诱导性股权奖励（统称 “诱导奖励”）于 2026 年 5 月 19 日（“授予日期”）授予了 Aura 的新首席执行官兼总裁 Natalie Holles。诱导奖励符合 Holles 女士的聘用信中先前披露的条款，并已根据纳斯达克上市规则 5635(c)(4) 获得公司董事会的批准。</p>
</div><p>The Inducement Awards consist of (i) non-qualified stock options to purchase an aggregate of 2,169,103 shares of the Company’s common stock (“Common Stock”) with an exercise price of $7.39 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date (the “Option Award”), (ii) restricted stock units (“RSUs”) for 600,118 shares of Common Stock, and (iii) performance-based RSUs (“PRSUs”) for 553,844 shares of Common Stock. The Option Award will vest as follows: 25% shall vest and become exercisable on April 30, 2027, and 2.0834% shall vest and become exercisable on a monthly basis thereafter over the following 36 months, subject to Ms. Holles’ continued service as of each vesting date. The RSUs will vest as follows: 25% shall vest on April 15, 2027 (the “First Vesting Date”), and 25% shall vest on each of the first year anniversary, second year anniversary, and third year anniversary of the First Vesting Date, subject to Ms. Holles’ continued service as of each vesting date. The PRSUs will be subject to both time-based vesting and the achievement of a performance condition, both of which must be satisfied before the PRSUs will be deemed vested. The PRSUs shall vest in four substantially equal annual installments commencing on the First Vesting Date, subject to Ms. Holles’ continued service as of each such time-based vesting date and the satisfaction of the performance condition. The expiration date of the PRSUs shall be the earlier of (i) the sixth (6th) anniversary of the Grant Date and (ii) the date Ms. Holles no longer has a service relationship with the Company. Any such PRSUs that have not vested on or prior to such expiration date shall be forfeited for no consideration.</p>
<div class="lb-trans"><p>诱导奖励包括（i）非合格股票期权，购买公司普通股（“普通股”）共计 2,169,103 股，行使价格为每股 7.39 美元，该价格等于授予日期纳斯达克报告的普通股收盘价（“期权奖励”）；（ii）600,118 股普通股的限制性股票单位（“RSUs”）；以及（iii）553,844 股普通股的基于业绩的限制性股票单位（“PRSUs”）。期权奖励的归属如下：25% 将在 2027 年 4 月 30 日归属并可行使，之后每月归属 2.0834%，在接下来的 36 个月内归属，前提是 Holles 女士在每个归属日期继续服务。RSUs 的归属如下：25% 将在 2027 年 4 月 15 日（“首次归属日期”）归属，之后在首次归属日期的第一年、第二年和第三年周年各归属 25%，前提是 Holles 女士在每个归属日期继续服务。PRSUs 将同时受到基于时间的归属和业绩条件的限制，只有在满足这两个条件后，PRSUs 才会被视为归属。PRSUs 将在首次归属日期开始的四个基本相等的年度分期中归属，前提是 Holles 女士在每个基于时间的归属日期继续服务，并满足业绩条件。PRSUs 的到期日为（i）授予日期的第六（6）周年或（ii）Holles 女士不再与公司有服务关系的日期，以较早者为准。在该到期日之前未归属的 PRSUs 将被没收，且不予任何补偿。</p>
</div><p><strong>About Aura Biosciences</strong></p>
<div class="lb-trans"><p><strong>关于 Aura Biosciences</strong></p>
</div><p>Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Aura’s lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura is headquartered in Boston, MA. Aura’s mission is to grow as an innovative global oncology company that positively transforms the lives of patients.</p>
<div class="lb-trans"><p>Aura Biosciences, Inc.是一家临床阶段的生物技术公司，专注于开发旨在保护器官功能的实体肿瘤精准疗法。Aura 的主要候选药物 bel-sar（AU-011）目前正在针对早期脉络膜黑色素瘤进行后期开发，并在其他眼肿瘤适应症和膀胱癌中进行早期开发。Aura 总部位于马萨诸塞州波士顿。Aura 的使命是成长为一家创新的全球肿瘤公司，积极改变患者的生活。</p>
</div><p>For more information, visit aurabiosciences.com. Follow us on X, @AuraBiosciences, and visit us on LinkedIn.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 aurabiosciences.com。关注我们在 X 上的动态，@AuraBiosciences，并访问我们的 LinkedIn 页面。</p>
</div><p><strong>Investor and Media Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体关系联系人：</strong></p>
</div><p>Alex Dasalla</p>
<div class="lb-trans"><p>Alex Dasalla</p>
</div><p>Head of Investor Relations and Corporate Communications</p>
<div class="lb-trans"><p>投资者关系和企业传播负责人</p>
</div><p>IR@aurabiosciences.com</p>
<div class="lb-trans"><p>IR@aurabiosciences.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU16TTROQ00zTmpFeU1USXhJelV3TURFeU5ESTJNQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMzM4NCM3NjEyMTIxIzUwMDEyNDI2MA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzQ5MDAxZTUtMmZjNi00OGIzLWI4OGQtN2M5N2Y3Y2FiNWViLTUwMDEyNDI2MC0yMDI2LTA1LTE5LWVu/tiny/Aura-Biosciences-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YzQ5MDAxZTUtMmZjNi00OGIzLWI4OGQtN2M5N2Y3Y2FiNWViLTUwMDEyNDI2MC0yMDI2LTA1LTE5LWVu/tiny/Aura-Biosciences-Inc-.png"/></p>

Aura Biosciences 宣布根据纳斯达克上市规则 5635(c)(4) 授予诱导性股票奖励 | AURA 股票新闻